GeoVax Labs Q2 2025 Financial Results and Business Update

GeoVax Labs, Inc. reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical programs. The company received favorable European regulatory guidance for its GEO-MVA vaccine, which supports a streamlined development pathway for the prevention of Mpox and smallpox. Additionally, GeoVax presented positive clinical data for its GEO-CM04S1 vaccine, demonstrating robust immune responses in patients with Chronic Lymphocytic Leukemia (CLL). The company also showcased strong safety and efficacy data for its Gedeptin® therapy in treating solid tumors. GeoVax reported a net loss of $5.4 million for the quarter, with government contract revenues of $852,282. The company ended the quarter with a cash balance of $3.1 million and completed a public offering in July 2025, raising approximately $5.6 million.